Spark Therapeutics has secured the exclusive rights to CombiGene’s CG01 therapy, which aims to treat drug resistant focal epilepsy, in a deal worth $8.5m in advance with further payments due on reaching clinical milestones.
The news sent Swedish firm CombiGene’s shares soaring – almost doubling from SEK6.29 to SEK14.10 the following day, when the development was announced this week. CombiGene could receive up to $328.5 million excluding royalties and up to $50 million at preclinical and clinical milestones. When it is commercialised, the firm could reap royalties, depending on net sales.